Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AMGEN INCAMGN · Entity 2832 | SVP, Business Development | August 11, 2026 | August 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AMGEN INC
Report date August 11, 2026 · Filed August 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,404 |
Reported balance
After 2026-08-11 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-11 · Sale · Disposed 2,000 · Balance 6,404 |
| Common StockSEC Table I · non-derivative | Direct | 7,656 |
Reported balance
After 2026-08-13 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-08-13 · Exercise / conversion · Acquired 1,252 · Balance 7,656 |
| Common StockSEC Table I · non-derivative | Direct | 6,404 |
Reported balance
After 2026-08-13 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2026-08-13 · Sale · Disposed 1,252 · Balance 6,404 F1: Includes shares sold to cover the option exercise price and required withholding taxes in connection with the exercise of expiring options. F2: These shares include 69 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. |
| Nqso (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $162.60 · Expires 2027-05-01 | Direct | 0 |
Reported balance
After 2026-08-13 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-08-13 · Exercise / conversion · Disposed 1,252 · Balance 0 |
Filing footnotes · ownership attribution and instrument terms
F1: Includes shares sold to cover the option exercise price and required withholding taxes in connection with the exercise of expiring options.
F2: These shares include 69 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 05, 2021 Filed Nov 10, 2021 01:13 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 1,169 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-028757 · form4.xml · nonDerivative · entry 1 Khosla Rachna · CIK 0001881332 · SVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,250 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 11/5/2023, 11/5/2024 and 11/5/2025, respectively. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.